OABI250117P7500
- 0.00
- 0.000.00%
OmniAb Newsroom
With 55% Institutional Ownership, OmniAb, Inc. (NASDAQ:OABI) Is a Favorite Amongst the Big Guns
Institutional Investors May Adopt Severe Steps After OmniAb, Inc.'s (NASDAQ:OABI) Latest 13% Drop Adds to a Year Losses
OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering & Therapeutics Conference
OmniAb, Inc. (NASDAQ:OABI) Just Reported And Analysts Have Been Cutting Their Estimates
Benchmark Co. Maintains OmniAb(OABI.US) With Buy Rating, Maintains Target Price $8
A Quick Look at Today's Ratings for OmniAb(OABI.US), With a Forecast Between $8 to $11
OmniAb Analyst Ratings
OmniAb's Robust Pipeline and Strategic Positioning Drive Buy Rating Despite Macroeconomic Challenges
OmniAb Down Over 9%, on Pace for Largest Percent Decrease Since November 2022 -- Data Talk
Strategic Partnerships and Financial Resilience: OmniAb's Path to Sustained Growth
RBC Capital Maintains OmniAb(OABI.US) With Buy Rating, Maintains Target Price $8
OmniAb (OABI) Receives a Buy From RBC Capital
TD Cowen Maintains OmniAb(OABI.US) With Buy Rating, Maintains Target Price $8
OmniAb, Inc. (OABI) Q3 2024 Earnings Call Transcript Summary
OmniAb, Inc. (OABI) Reports Q3 Loss, Lags Revenue Estimates
10-Q: Q3 2024 Earnings Report
OmniAb Sees FY24 Cash Balance $50M-$60M
OmniAb GAAP EPS of -$0.16 Misses by $0.02, Revenue of $4.2M Misses by $4.2M
8-K: OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights
Earnings Flash (OABI) OMNIAB Posts Q3 Revenue $4.2M